Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells

Journal of Cellular Biochemistry

Volumn 104, Issue 3, 2008, Pages 1102-1112

  Mi, Ha Kim ^a   Jung, Sun Park ^a   Hee, Jung Chang ^a   Min, Kyung Baek ^a   Hyeong, Rok Kim ^a   Boo, Ahn Shin ^a   Bong, Whan Ahn ^a   Young, Do Jung ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Gastric cancer; Invasion; LPA; Signaling; uPAR

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; NEUTRALIZING ANTIBODY; PROTEIN C JUN; PROTEIN CDC42; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1; UROKINASE RECEPTOR; WORTMANNIN;

ARTICLE; CANCER INVASION; CELL INVASION; EXPRESSION VECTOR; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STOMACH CANCER;

CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; COLLAGEN; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; LYSOPHOSPHOLIPIDS; NEOPLASM INVASIVENESS; NF-KAPPA B; PROMOTER REGIONS (GENETICS); PROTEOGLYCANS; RECEPTORS, CELL SURFACE; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

EID: 45149095189     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21696     Document Type: Article

References (29)

1. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi R, Arai H. 2002. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 277:8737-48744.
2. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. 1997. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 79:878-883.
3. Etienne-Manneville S, Hall A. 2002. Rho GTPases in cell biology. Nature 420:629-635.
4. Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N, Sivashanmugam P, Moniri NH, Daaka Y. 2006. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147:4883-4892.
5. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, Jaffe RB. 2001. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93:762-768.
6. Hwang YS, Hodge JC, Sivapurapu N, Lindholm PF. 2006. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. Mol Carcinog 45:518-529.
7. Kaneyuki U, Ueda S, Yamagishi S, Kato S, Fujimura T, Shibata R, Hayashida A, Yoshimura J, Kojiro M, Oshima K, Okuda S. 2007. Pitavastatin inhibits lysophos phatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul Pharmacol 46:286-292.
8. Katabami M, Donninger H, Hommura F, Leaner VD, Kinoshita I, Chick JF, Birrer MJ. 2005. Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells. J Biol Chem 280:16728-16738.
9. Kim MH, Yoo HS, Chang HJ, Hong MH, Kim HD, Chung IJ, Shin BA, Cho MJ, Ahn BW, Jung YD. 2005. Urokinase plasminogen activator receptor is upregulated by Helicobacter pylori in human gastric cancer AGS cells via ERK, JNK, and AP-1. Biochem Biophys Res Commun 333:874-880.
10. Li H, Ye X, Mahanivong C, Bian D, Chun J, Huang S. 2005. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem 280:10564-10571.
11. Lund LR, Green KA, Stoop AA, Ploug M, Almholt K, Lilla J, Nielsen BS, Christensen IJ, Craik CS, Werb Z, Dano K, Romer J. 2006. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J 25:2686-2697.
12. Manning AM, Davis RJ. 2003. Targeting JNK for therapeutic benefit: From junk to gold? Nat Rev Drug Discov 2:554-565.
13. Masuda M, Minami M, Shime H, Matsuzawa T, Horiguchi Y. 2002. In vivo modifications of small GTPase Rac and Cdc42 by Bordetella dermonecrotic toxin. Infect Immun 70:998-1001.
14. Moolenaar WH. 1999. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253:230-238.
15. Pages C, Simon M, Valet P, Saulnier-Blache JS. 2001. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 64:1-10.
16. Parkin DM, Bray F, Ferlay J, Pisani P. 2002. Global cancer statistics. CA Cancer J Clin 55:74-108.
17. Price LS, Collard JG. 2001. Regulation of the cytoskeleton by Rho-family GTPases: Implications for tumour cell invasion. Semin Cancer Biol 11:167-173.
18. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. 2005. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280:36529-36540.
19. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. 2004. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 92:949-966.
20. Saatian B, Zhao Y, He D, Georas SN, Watkins T, Spannhake EW, Natarajan V. 2006. Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem J 393:657-668.
21. Smicun Y, Gil O, Devine K, Fishman DA. 2007. S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells. Gynecol Oncol 107:298-309.
22. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS. 2005. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 65:2234-2242.
23. Van Leeuwen FN, Giepmans BN, Van Meeteren LA, Moolenaar WH. 2003. Lysophosphatidic acid: Mitogen and motility factor. Biochem Soc Trans 31:1209-1212.
24. Waltz DA, Fujita RM, Yang X, Natkin L, Zhuo S, Gerard CJ, Rosenberg S, Chapman HA. 2000. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol 22:316-322.
25. Wang Y, Dang J, Wang H, Allgayer H, Murrel GA, Boyd D. 2000. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem 267:3248-3254.
26. Wei Y, Tang CH, Kim Y, Robillard L, Zhang F, Kugler MC, Chapman HA. 2007. Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J Biol Chem 282:3929-3939.
27. Wu WT, Chen CN, Lin CI, Chen JH, Lee H. 2005. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 146:3387-3400.
28. Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H. 2006. Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol 93:30-35.
29. Zhao Y, Usatyuk PV, Cummings R, Saatian B, He D, Watkins T, Morris A, Spannhake EW, Brindley DN, Natarajan V. 2005. Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. Biochem J 385:493-502.